Lenvatinib plus pembrolizumab improves PFS, OS, ORR across RCC subgroups
16 Jun 2021
byChristina Lau
First-line treatment with lenvatinib plus pembrolizumab improves progression-free survival (PFS), overall survival (OS) and objective response rate (ORR) vs sunitinib across subgroups of patients with advanced renal cell carcinoma (RCC), and maintains or improves patients’ health-related quality of life (HRQoL), new data from the CLEAR trial have shown.
Lenvatinib plus pembrolizumab improves PFS, OS, ORR across RCC subgroups
16 Jun 2021